Recent research demonstrates that GLP-1 receptor agonists, which are medications that mimic the gut hormone glucagon-like peptide-1 to stimulate insulin release, help increase feelings of fullness before eating by influencing neural pathways in the hypothalamus, potentially aiding in obesity management by modifying responses to food cues and perceptions.
A new study reveals that GLP-1 receptor agonists enhance the feeling of fullness before eating by affecting neurons in the dorsomedial hypothalamus, offering insights into their role in preventing overeating and treating obesity. A new study has found that GLP-1 receptor agonists trigger sensations of fullness prior to eating by acting on neurons in the dorsomedial hypothalamus. This research sheds light on the neural mechanisms through which these agonists enhance satiety and help prevent excessive food intake, playing a crucial role in addressing obesity.
Glucagon-like-peptide-1 plays an important role in signaling the feeling of fullness after eating. Preingestive satiation is a phenomenon that occurs before actual food intake, allowing animals to regulate internal status and prepare for changes. Recently, GLP-1 receptor agonists have proven effective in treating obesity by affecting food cognition, diminishing hypothalamic responses to food cues, and altering food palatability perception.
Reference: “GLP-1 increases preingestive satiation via hypothalamic circuits in mice and humans” by Kyu Sik Kim, Joon Seok Park, Eunsang Hwang, Min Jung Park, Hwa Yun Shin, Young Hee Lee, Kyung Min Kim, Laurent Gautron, Elizabeth Godschall, Bryan Portillo, Kyle Grose, Sang-Ho Jung, So Lin Baek, Young Hyun Yun, Doyeon Lee, Eunseong Kim, Jason Ajwani, Seong Ho Yoo, Ali D. Güler, Kevin W.